Increasing unusual put option volume: CAPR BETA UCO CRH BKR METC OTLK CIA TCOM EQNR
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St set to open lower as oil jump, high yields fuel inflation concerns
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Lynx sees AI semiconductor rally extending into year-end
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
Jones Trading on Capricor Therapeutics (CAPR): 'this is the first time we have seen the magnitude of difference in primary outcome'
July 27, 2026 2:36 PM EDTJones Trading analyst Catherine Novack reiterated a Buy rating and $51.00 price target on Capricor Therapeutics (NASDAQ: CAPR).
The analyst comments "What's New: FDA released briefing documents ahead of the July 29 AdCom meeting for deramiocel (LINK). The reviewers concluded that deramiocel studies did NOT provide substantial evidence of effectiveness... More
H.C. Wainwright on Capricor Therapeutics (CAPR): 'Cage Match Expected at Wednesday's AdCom as Drama with FDA Continues'
July 27, 2026 12:31 PM EDTH.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $60.00 price target on Capricor Therapeutics (NASDAQ: CAPR).
The analyst comments "The timing of the SAP revisions raises questions regarding functional unblinding. The FDA acknowledges that SAP Versions 2.0 and 3.0 were finalized before formal database lock and unblinding, but notes that the randomized, double-blind treatment period had already ended. The FDA also... More



